Citigroup sours on Bavarian Nordic's Covid-19 vaccine, is skeptical of RSV candidate
The investment bank removes Bavarian Nordic’s potential Covid-19 vaccine sales from its estimates, and subsequently lowers its share price target for the drugmaker.
by ulrich quistgaard, translated by daniel pedersen
Investment bank Citigroup has completely lost faith in Danish vaccine maker Bavarian Nordic making sales from its Covid-19 candidate, and pharmaceutical analyst Peter Verdult is also reducing his optimism for the company’s candidate against respiratory syncytial virus (RSV).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
